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Background/aim: Parvovirus risk in blood transfusion has become a popular research topic since there are limited data on parvovirus
seroprevalence in blood donors in Turkey. The aim of this study was to investigate parvovirus seroprevalence in blood donors in Turkey.
Materials and methods: Blood samples of 988 blood donors admitted to a university blood bank were obtained for parvovirus B19 IgM
and IgG detection. The samples were analyzed using the ELISA method.
Results: IgM positivity of 3.92% and IgG positivity of 58.9% was detected in the blood samples. Parvovirus IgM positivity was found to
be the highest in the age group of 41–50 years (P = 0.045) and IgG positivity was detected to be the highest in the age group of 31–40
years (P < 0.001). Parvovirus IgG positivity was significantly higher in women (P = 0.041). However, there was no difference regarding
parvovirus IgM positivity in terms of sex (P = 0.245).
Conclusion: Although this study does not represent the whole country, it is still the largest investigation carried out on the topic in
Turkey and the obtained results are generally similar to those of European countries. Therefore, it is thought that the results obtained
from this study may be supportive for the first steps regarding plasma fractionation, which will soon begin in Turkey.
Key words: Transfusion medicine, ELISA, blood banking, parvovirus

1. Introduction
Human parvovirus B19 (PVB19) is a nonenveloped
member of the family Parvoviridae. It typically infects
erythroid precursor cells and has a cytotoxic effect on
them. Therefore, a pause of erythropoiesis occurs, which
is the most obvious feature of parvovirus infections. In
many patients this transient pause of erythropoiesis does
not cause a problem; however, in those with problems such
as hemolytic anemia, severe aplastic anemia crisis might
be seen (1,2).
The virus is generally spread by respiratory route, but
blood transfusion is an alternative transmission route (3).
PVB19 viremia occurs 1 week after the exposure and lasts
at least 5 days. It reaches its highest level on the second day.
Towards the end of the viremic period, immunoglobulin
M (IgM) antibodies are detected. Generally, this detection
is on days 10–14 of the infection. IgM positivity lasts until
the 5th month. However, in some people, it may last longer.
Immunoglobulin G (IgG) type antibodies become positive
after 15 days and stay positive at higher titers for months.
These antibodies can be analyzed using enzyme-linked

immunosorbent assay (ELISA), radioimmunoassay, and
chemiluminescence or immunofluorescence methods (4).
Although epidemiological features of the infection do not
change, IgG positivity is found in 2%–21% of children at
ages range between 1 and 5, in 30%–40% of adolescents, in
40%–60% of adults, and in more than 85% of the elderly
population (5).
The main objective of professionals dealing with
this issue is to ensure access to safe and effective blood
components for patients who are in need of blood
transfusion. Blood products obtained from plasma pools
and PVB19 contamination are especially important for
blood banking (5). Iatrogenic transmission is seen when
a high level of viremia is present in the primary infection
or if there is a virus load of more than 1012 geq/mL in early
periods of acute infection in asymptomatic blood donors
(6). However, in plasma products processed with solvent
detergent technology, though HIV and hepatitis B and C
are inactive, PVB19 is not affected because of its nonlipid
enveloped structure. It is also resistant to heat and if the
plasma is exposed to dry air at 80 °C for 72 h, there is no
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inactivation (5). PVB19 DNAs are detected in 50%–80%
of nonviral inactivated factor VIII concentrates and
30%–50% of IX concentrates inactivated with the solvent/
detergent method (7). However, there are limited data
on patients having symptomatic infections transmitted
by virus-containing blood components. Most cases of
seroconversion are shown in asymptomatic receivers (8).
Infection does not occur if the PVB19 viral load of
plasma-derived products is less than 103–104 geq/mL. The
explanation for this might be the inadequacy of the amount
causing an infection or the existence of neutralizing
antibodies in the pool from which the plasma-derived
products were obtained. Receiver factors also have an
important role in the infection. PVB19 antibodies hinder
reinfection and most adults have seropositivity for PVB19
(9,10). However, in the United States and Europe, there
is permission for a maximum of 104 PVB19 viral load in
plasma-derived blood products (11,12).
The prevention of parvovirus B19 transmission is
especially important for patient groups with immune
deficiency or hemolytic anemia. In these groups, a viral
load of more than 107 presents a high risk (4,9).
To prevent the use of PVB19-contaminated blood
components is the only way to prevent the transmission of
this infection via blood.
2. Materials and methods
2.1. Study design
Nine hundred and eighty-eight blood samples were taken
from individuals admitted to a university blood bank
between 2012 and 2014. They were eligible for blood
donation (based on blood donor database registers, blood
donor questionnaires, and whole blood count results).
Blood samples were centrifuged and separated serums
were kept at –80 °C until study time. All procedures
performed in studies involving human participants
were in accordance with the ethical standards of the
institutional and/or national research committee and with
the 1964 Helsinki declaration and its later amendments
or comparable ethical standards. The blood samples were
taken from the blood donors in accordance with Gazi
University Medical Faculty Ethics Committee Approval
Document No. 184.
2.2. Detection of parvovirus B19 IgM and IgG antibodies
For parvovirus B19 IgM and IgG detection, two different
commercial ELISA kits were employed. The NovaLisa
parvovirus B19 IgM and IgG ELISA kits (NovaTec
Immundiagnostica GmbH, Germany) were used for
PVB19 screening and PVB19 IgM-positive samples and
90 randomized IgG-positive samples were confirmed
via DRG parvovirus B19 IgM and IgG ELISA kit (DRG
Instruments GmbH, Germany). The serum samples were
diluted with sample dilution buffer at a ratio of 1:100 for

DRG IgG and NovaLisa IgM and IgG tests. For DRG IgM
assay, the serum samples were diluted at a ratio of 1:50, then
diluted again with an IgG-RF-Sorbent solution within the
kit at a ratio of 1:1. The assays were performed according
to the manufacturer’s instructions. At the end of the study,
optical densities (ODs) of the wells in the microplate were
measured in 450/620 nm wavelength (Plate Reader, DAS,
Italy) and the results were evaluated.
2.3. Evaluation of the results
According to validation measurements of the assay in the
NovaLisa Parvovirus B19 IgM and IgG ELISA kits, the
test is considered to be operated properly if the substrate
blank well is less than 0.100, the negative control is less
than 0.200, the cut-off value is between 0.150 and 1.300,
and the positive control is higher than the cut-off value.
The mean of the two cut-off values is taken. If OD values
of the samples are 10% and higher than the cut-off value,
the result is considered as positive, and if they are lower,
the result is considered to be negative. The sensitivity and
specificity of the kit were indicated as 95%.
According to the DRG parvovirus B19 IgM and IgG
ELISA kits, the test is considered to be performed properly
if the substrate blank well is less than 0.100, the negative
control is less than 0.200, the cut-off value is between 0.350
and 0.850, and the positive control is between 0.650 and
3.000. The mean of the two cut-off values was taken. If OD
values of the cut-off value were 20% and higher than the
cut-off value, the result was positive. If they were 15% and
lower, it was negative. The instruction manual of the kit
declared sensitivity and specificity as 100%.
2.4. Statistical analysis
SPSS 15 (SPSS Inc., Chicago IL, USA) was used for the
evaluation of the data obtained from the study and to
form tables. The data were presented in tables as numbers
and percentages. The differences between parvovirus IgM
and parvovirus IgG positivity regarding both sex and age
groups were analyzed using the Pearson chi-square test.
Finally, the significance level was P < 0.05 in all statistical
analysis.
3. Results
The results obtained at the end of the study and their
distribution concerning age and sex are presented in
Tables 1 and 2.
There was a significant difference between both
parvovirus IgM (χ2 = 8.038; P = 0.045) and IgG positivity
rates (χ2 = 69.003; P < 0.001) in terms of age. Parvovirus
IgM positivity was at its highest rate in the age group of
41–50 years and lowest in the 18–30 age group. On the
other hand, the parvovirus IgG positivity rate was highest
at 31–40 years and lowest at ≥51 years. Although there
was no significant difference between parvovirus IgM
positivity in terms of sex (χ2 = 1.354; P = 0.245), parvovirus
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Table 1. Distribution of parvovirus IgM and IgG positivity according to age groups.
Age groups Blood donors number

IgM positivity number IgM positivity percent IgG positivity number IgG positivity percent

18–30

336

8

2.38

202

60.3

31–40

280

14

5

200

71.7

41–50

154

11

7.14

100

64.7

51–65

218

6

2.75

80

36.6

Total

988

39

3.9

582

58.9

Table 2. Distribution of blood donors according to age groups
and sex.
Blood donors age groups

Male

Female

Total

18–30
31–40
41–50
51–65

268
222
104
189

68
58
50
29

336
280
154
218

Total

783

205

988

IgG positivity rates were significantly different (χ2 = 4.192;
P = 0.041). Finally, the parvovirus IgG positivity rate
was significantly higher in women (65.40%) than men
(57.20%).
4. Discussion
Due to advances in transfusion medicine, blood-borne
viral infection frequency has decreased recently. This
was achieved using certain strategies such as blood
donor selection, development of screening methods
for the viral organism, and widespread use of viral
inactivation methods concurrently. The use of nucleic acid
amplification technologies has also shortened the window
period and contributed to blood transfusion safety. PVB19
may lead to serious clinical complications in pregnant
women, children with hematological problems, and
patients with immune deficiencies. If parvovirus is studied
using different methods to analyze the blood of donors,
one parvovirus case in 20,000 to 50,000 donations can be
detected. In epidemic periods, this can be as high as one
case in 260 blood donors (13).
In Turkey, there are limited data on parvovirus
epidemiology. Türk Dağı et al. investigated IgG frequency
in a study carried out in Konya in 2010. Their study group
included blood donors 18–60 years old and children
admitted to the hospital for various reasons. In 631 blood
donors from the adult group, PVB19 IgG positivity was
36% (14). In 2012 Motor et al. analyzed parvovirus B19
seroprevalence in adults with essential hypertension in
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Hatay. In the 45 individuals who formed the healthy
control group of the study, IgM positivity was 15.6%
and IgG positivity was 31% (15). Moreover, Erden et al.
evaluated the relation between Hashimoto thyroiditis and
PVB19 infection in 2013. In healthy participants making
up the control group in this study, the IgM positivity was
5.7% and the IgG positivity was 22.9% (16). Motor et al.
analyzed the role of parvovirus in patients with ankylosing
spondylitis in 2014. In the control group of this study,
IgM positivity was 4.3% and IgG positivity was 30% (17).
On the other hand, an IgM positivity of 3.9% and an IgG
positivity of 58.9% were determined in our study. In all the
studies mentioned above, the results showed significant
variations. These variations may have occurred because all
the data except one set came from control groups; there
may also be seasonal and/or geographical differences,
there are variations in the age distributions among the
groups, and, finally, the study groups in other studies were
not large enough.
The frequency of IgG antibodies against parvovirus
B19 infection increases with age and has geographical
differences. In Chile in 2007, for example, the frequency in
blood donors (18–64 years old) was 54.8% (18), which is
in accordance with our results. In Poland, the first peak for
parvovirus infection was at a preschool age and by the age
of 40 the rate was as high as 80% (19). Furthermore, 40% of
women of child-bearing age were reported to be at risk of
parvovirus B19 infection, especially during epidemic years.
In Australia, seroprevalence for parvovirus B19 was 51% at
ages of 10–19 and 78% at ages of >50 (20). In England and
Wales, seropositivity was 50%–60% in young adults, but
85% after the age of 70 (21). A study done in blood donors
in 2004 in Italy revealed that the seropositivity rate was
77% between the ages of 18 and 27, and the rate was 88.5%
between the ages of 48 and 57 (22). However, the highest
seropositivity rate was found between the ages of 31 and 40
in our study. In contrast with the literature, it was observed
that there is a significant decrease in the seropositivity rate
especially after 50 years.
Seropositivity rates of parvovirus infection indicate
geographical differences. In Far East Asian countries
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seropositivity is lower than in the western world. For
example, in Thailand, this rate was 10.94% in young adults
in 2003 (23). In another Far East country, Malaysia, this
rate for the same age group was 32% in 2002 (24). In a
similar study carried out in 1998 in Spain, IgG antibodies
were positive in 64.7% of blood donors, but IgM antibodies
were not found in any participants (25). While the
seropositivity rate of blood donors in Belgium was 74%,
that of blood donors in Tunisia was 65% in 1997. This
difference might originate from geographical differences
between north and south (26).
The methods that decrease parvovirus transmission
in transfusion medicine are still under investigation.
Among these methods being discussed are the nucleic acid
amplification test (NAT), in which screening is done in a
single case or in a small number of pools, and techniques
that are applied in viral inactivation and detergent solvent
methods such as multiple steps of superheating (3 days at
80 °C), pasteurization, and nanofiltration (27). Screening

of all blood donation with NAT-based algorithms is
performed in Germany, Austria, Poland, and Japan
(28,29). Not using plasma with higher than a certain
amount of viral load (105 IU/mL) decreases the viral load
in plasma pools and also diminishes the seroconversion
or transmission rate of symptomatic diseases. However,
this may destroy much of the plasma, so the maintenance
of the system should be guaranteed (5). However, low
transmission risk with transfusion brings the question of
availability, especially in low endemic countries (30).
The largest study that shows the parvovirus B19
seroprevalence in blood donors in Turkey was performed
in this research and the ratios changing with age and sex
were also presented.
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